Abstract
Off-label prescribing is an essential component of good medical care, and it offers greater choice in treatment options for millions of patients. Food and Drug Administration rules prohibit manufacturers from disseminating most information about off-label uses, though, making it difficult for doctors and their patients to learn about important therapeutic options. The prohibition on truthful and non-misleading speech raises constitutionality questions, which have not yet been fully explored by courts. This paper examines the role of off-label prescribing in medical practice and the regulation of off-label promotion. It also discusses the scope of permissible commercial speech regulation and analyzes the constitutionality of off-label speech restrictions in light of applicable case law. It concludes that the FDA’s ban on off-label promotion is unconstitutional, but suggests less burdensome alternative restrictions that likely would pass constitutional muster while still advancing the government’s asserted interests.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
